Genetic and biochemical risks factors in coronary artery disease

Boekholdt, S.M.

Citation for published version (APA):

General rights
It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

Disclaimer/Complaints regulations
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: http://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.
Contents

Chapter 1
General introduction and outline of the thesis

Part I: Lipids, Lipoproteins and Apolipoproteins

Chapter 2
Molecular variation at the apolipoprotein B gene locus in relation to lipids and cardiovascular disease; a systematic meta-analysis
Human Genetics 2003; 113: 417-425

Chapter 3
The ratio of apolipoproteins B to A-I and the risk of future coronary artery disease in apparently healthy men and women; the EPIC-Norfolk prospective population study
Submitted

Chapter 4
CETP gene variation: relation to lipid parameters and cardiovascular risk
Current Opinion in Lipidology 2004; 15: 393-398

Chapter 5
The cholesteryl ester transfer protein (CETP) TaqIB variant, HDL cholesterol levels, cardiovascular risk and the efficacy of pravastatin treatment; an individual patient meta-analysis of 13,677 subjects
Circulation 2005; 111: 278-287

Chapter 6
Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women; the prospective EPIC-Norfolk population study
Circulation 2004; 110: 1418-1423

Chapter 7
CETP, HDL-c, and cardiovascular risk: Will CETP inhibition translate into cardiovascular risk reduction?
Arteriosclerosis Thrombosis and Vascular Biology 2005; In Press
Part II: Oxidation and Inflammation

Chapter 8
Serum levels of type II secretory phospholipase A2 and the risk of future coronary artery disease in apparently healthy men and women; the EPIC-Norfolk prospective population study
*Arteriosclerosis Thrombosis and Vascular Biology* 2005; In Press

Chapter 9
Variants of toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events
*Circulation* 2003; 107: 2416-2421

Chapter 10
IL-8 plasma concentrations and the risk of future coronary heart disease in apparently healthy men and women; the EPIC-Norfolk prospective population study
*Arteriosclerosis Thrombosis and Vascular Biology* 2004; 24: 1-7

Chapter 11
Macrophage migration inhibitory factor and the risk of myocardial infarction or death due to coronary artery disease in adults without prior myocardial infarction or stroke; the EPIC-Norfolk prospective population study
*American Journal of Medicine* 2004; 117: 390-397

Chapter 12
C-reactive protein and the prediction of coronary artery disease incidence and mortality in apparently healthy men and women; the EPIC-Norfolk prospective population study 1993-2003
Submitted

Part III: Coagulation and Fibrinolysis

Chapter 13
Interaction between a genetic variant of the platelet fibrinogen receptor and fibrinogen levels in determining the risk of cardiovascular events.
*American Heart Journal* 2004; 147: 181-186
Chapter 14
Genetic variation in coagulation and fibrinolytic proteins and their relation with acute myocardial infarction; a systematic review
*Circulation* 2001; 104: 3063-3068

Chapter 15
Fibrinogen plasma levels, the factor XIII Val34Leu variant and the risk of future coronary artery disease; the EPIC-Norfolk prospective population study
*Interim analysis*

Summary and conclusion

Samenvatting en conclusie

List of publications

Dankwoord

Curriculum vitae